| APO |
Report |
Fee-related earnings |
BEAT |
pred ~$780M vs. cons $766.5M |
MEDIUM |
| APO |
Report |
Spread-related earnings |
MISS |
pred ~$860M vs. cons $874.4M |
MEDIUM |
| APO |
Report |
Gross capital deployment |
BEAT |
pred ~$100B vs. cons $96.6B |
MEDIUM |
| APO |
Guide |
FRE growth (FY26) |
LOWER |
guide 20%+ floor, ~$3.03B, vs. cons $3.11B |
LOW |
| APO |
Guide |
SRE growth (FY26) |
BETTER |
guide 10%, ~$3.70B, vs. cons $3.48B |
MEDIUM |
| APO |
Guide |
Origination / ACS commentary (Q3) |
UNCHANGED |
strong pipeline commentary vs. UNVERIFIED consensus |
LOW |
| APO |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.0% |
— |
LOW |
| APO |
Return |
5-day cumulative residual |
-4.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — SRE estimate risk outweighs a FRE/deployment beat |
LOW |